David Band to Step Down from Pacific Edge Board

18 July 2018
Company Announcement

DAVID BAND TO STEP DOWN FROM PACIFIC EDGE BOARD

Pacific Edge Limited (NZX:PEB) advises that long serving Director, David Band, has indicated that he will step down
from the Board at the upcoming Annual Meeting, to be held in August 2018.

David was appointed to the Board in 2007 and has held the position of Deputy Chair for most of his tenure.
He has also been a member of a number of the Company’s subsidiary Boards and advisory committees.

Chair of Pacific Edge, Chris Gallaher, said: “David has made a significant contribution to Pacific Edge as the
Company has developed its unique molecular diagnostic technology and embarked on its commercial
journey. His experience in the life sciences sector, and expertise in corporate governance, talent
management and commercialisation of innovation have been a key factor in Pacific Edge’s successful
evolution from R&D to commercial reality.”

David said: “It has been a privilege to have been able to contribute to the development and launch of
Cxbladder, a diagnostic test that enables better care, better clinical decision making and better use of
healthcare resources. As the Company moves ever close to commercial success, I believe it is now time to
step down and allow for fresh thinking and skills to take the Company forward.”

Pacific Edge will take the opportunity to acknowledge David’s contributions at the Annual Shareholders
Meeting.

The Board has a process underway to identify and appoint a new Director.

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery
and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder
suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and
management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder
cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s
products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of
patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who
have a low probability of having urothelial carcinoma.

18 July 2018
Company Announcement
ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of
a patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence
of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer
has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients
with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of
recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in
the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer.
Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other
Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability
of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be
warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.